Plain-English translation of NCT06409936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it works well for people who have just been diagnosed with chronic myeloid leukemia (a type of blood cancer). Some patients will take by itself, while others will take it combined with another medication called . The goal is to understand which approach works best and is safest for newly diagnosed patients.
Current standard treatments for this blood cancer work well, but doctors are looking for better options that may be even more effective or cause fewer side effects. This medication is being studied to see if it could become a new first-line treatment choice for patients newly diagnosed with this disease.
You likely qualify if…
You likely don't qualify if…
You will take either the new medication alone or in combination with another medication for at least 2 years, with regular blood tests to monitor how well the treatment is working and to watch for side effects. If your cancer reaches a deep level of remission (very few or no remaining cancer cells), you may be able to continue on a lower dose for another 2 years and eventually stop treatment altogether while being closely monitored. The study involves regular clinic visits and frequent blood work to track your response to treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Spain